Elevated expression of S100A3 was found primarily in ovarian cancer cells resistant to cisplatin and paclitaxel, both standard chemotherapeutic drugs, as well as topotecan, a chemotherapeutic agent commonly used in second-line treatment [146]. This evidence concerns the gene S100A3 and ovarian carcinoma.